Order Article Reprints

Guezour N, Soussi G, Brosseau S, Abbar B, Naltet C, Vauchier C, Poté N, Hachon L, Namour C, Khalil A, et al. Grade 3–4 Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer (NSCLC) Patients Are Correlated with Better Outcome: A Real-Life Observational Study. Cancers. 2022; 14(16):3878. https://doi.org/10.3390/cancers14163878

Guezour, Nadia, Ghassen Soussi, Solenn Brosseau, Baptiste Abbar, Charles Naltet, Charles Vauchier, Nicolas Poté, Lorry Hachon, Céline Namour, Antoine Khalil, and et al. 2022. "Grade 3–4 Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer (NSCLC) Patients Are Correlated with Better Outcome: A Real-Life Observational Study" Cancers 14, no. 16: 3878. https://doi.org/10.3390/cancers14163878

Guezour, N., Soussi, G., Brosseau, S., Abbar, B., Naltet, C., Vauchier, C., Poté, N., Hachon, L., Namour, C., Khalil, A., Trédaniel, J., Zalcman, G., & Gounant, V. (2022). Grade 3–4 Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer (NSCLC) Patients Are Correlated with Better Outcome: A Real-Life Observational Study. Cancers, 14(16), 3878. https://doi.org/10.3390/cancers14163878